keyword
MENU ▼
Read by QxMD icon Read
search

BRVO

keyword
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#1
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28316837/combination-of-navigated-macular-laser-photocoagulation-and-anti-vegf-therapy-precise-treatment-for-macular-edema-under-dry-retinal-conditions
#2
Ernest V Boiko, Dmitrii S Maltsev
Purpose. To compare the controllability of navigated macular laser photocoagulation (MLP) in dry versus edematous retina and validate that pretreatment diagnostic images can be used as basis for navigated MLP after the macular edema (ME) has been resolved. Materials and Methods. Group 1 was divided into subgroup 1 (dry retina MLP) and subgroup 2 (MLP in ME) for comparisons of laser-burn diameters. In group 2, the areas and locations of ME before an intravitreal injection of anti-VEGF (IVAV) were compared with those of recurrent ME...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315518/real-world-outcomes-of-anti-vegf-treatment-for-retinal-vein-occlusion-in-portugal
#3
Sara Vaz-Pereira, Inês P Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores
PURPOSE: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. METHODS: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment...
February 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315513/increased-fibrinogen-to-albumin-ratio-in-ischemic-retinal-vein-occlusions
#4
Hande Guclu, Sadık A Ozal, Vuslat Pelitli Gurlu, Gülben Sayılan Özgün, Eray Özgün
PURPOSE: To demonstrate the relationship between ischemia and plasma fibrinogen and serum albumin levels in cases of retinal vein occlusion (RVO). METHODS: This study included 44 patients with central RVO (CRVO), 68 patients with branch RVO (BRVO), and 54 age- and sex-matched controls, for a total of 166 subjects. All of the subjects underwent full ophthalmologic examinations and complete physical examinations, including a detailed medical history and blood count, and biochemical parameters...
March 3, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28288603/a-cute-angle-closure-attack-after-an-intravitreal-bevacizumab-injection-for-branch-retinal-vein-occlusion-a-case-report
#5
Seongyong Jeong, Min Sagong, Woohyok Chang
BACKGROUND: Intravitreal injection is widely used to treat retinal vein occlusion, and acute angle closure (AAC) is an exceptional complication of intravitreal injection. The authors report a case of AAC that occurred immediately after administering intravitreal bevacizumab to treat branch retinal vein occlusion (BRVO). CASE PRESENTATION: A 65-year-old woman was referred to the retina clinic of a tertiary referral center for the treatment of macular edema secondary to BRVO...
March 14, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28266152/macular-cystic-changes-as-predictive-factor-for-the-recurrence-of-macular-oedema-in-branch-retinal-vein-occlusion
#6
Eric Tilgner, Maiara Dalcegio Favretto, Maria Tuisl, Peter Wiedemann, Matus Rehak
AIM: To evaluate the role of small cystic macular changes as a prognostic factor for the recurrence of macular oedema (ME) in patients with branch retinal vein occlusion (BRVO) treated with anti-VEGF drugs. METHODS: We performed retrospective chart analysis of 116 patients treated with intravitreal injection of ranibizumab (IVR) or bevacizumab (IVB) for ME secondary to BRVO. At the baseline and monthly follow-up visits over a period of 12 months, a comprehensive ophthalmologic examination including best-corrected visual acuity (BCVA) and volume scan of macula using Spectral domain optical coherence tomography (SD-OCT) were performed...
March 7, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28260852/prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion
#7
Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi
PURPOSE: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in daily practice. MATERIALS AND METHODS: This retrospective study enrolled 15 eyes in 15 Japanese patients with ME secondary to BRVO who had been receiving a pro re nata regimen of ranibizumab and had provided written informed consent to switch to aflibercept therapy...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28255227/five-year-outcomes-of-pars-plana-vitrectomy-for-macular-edema-associated-with-branch-retinal-vein-occlusion
#8
Akihiro Nishida, Hiroshi Kojima, Takanori Kameda, Michiko Mandai, Yasuo Kurimoto
PURPOSE: Long-term outcomes of pars plana vitrectomy (PPV) for macular edema (ME) associated with branch retinal vein occlusion (BRVO) have been previously reported, but the studies did not report the number of additional treatments after surgery. During 5 years of follow-up, we therefore investigated the efficacy and safety of PPV for BRVO and evaluated the incidence of additional treatments. METHODS: We retrospectively reviewed the medical records of 25 eyes of 24 patients who underwent PPV for ME associated with BRVO and were followed up for at least 5 years...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28251811/head-to-head-comparison-of-ranibizumab-prn-versus-single-dose-dexamethasone-for-branch-retinal-vein-occlusion-comrade-b
#9
Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, Steffen Schmitz-Valckenberg, Hüsnü Berk, Nicole Eter, Gabriele E Lang, Matus Rehak, Simon R Taylor, Armin Wolf, Claudia Weiss, Eva-Maria Paulus, Amelie Pielen, Hans Hoerauf
PURPOSE: To compare the efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg according to their European labels in macular oedema secondary to branch retinal vein occlusion (BRVO) in a 6-month, phase IIIb, randomized trial. METHODS: Patients received either monthly ranibizumab for 3 months followed by Pro re nata (PRN) treatment (n = 126) or a sustained-release dexamethasone implant followed by PRN sham injections (n = 118). Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to month 1 through month 6, mean changes in BCVA and foveal centre point thickness (FCPT), and adverse events (AEs)...
March 2, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28251087/retinal-vessel-oxygen-saturation-in-healthy-subjects-and-early-branch-retinal-vein-occlusion
#10
Jing-Yan Yang, Bing You, Qian Wang, Szy Yann Chan, Jost B Jonas, Wen-Bin Wei
AIM: To measure the retinal oxygen saturation in healthy subjects and early branch retinal vein occlusion (BRVO) in Chinese population. METHODS: The retinal vessel oxygen saturation of the healthy subjects and BRVO patients were measured by a noninvasive retinal oximeter (Oxymap ehf., Reykjavik, Iceland). RESULTS: The study included 22 patients with unilateral BRVO (mean age: 55.1±8.8y) in the study group and 91 healthy participants (mean age: 37...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28247073/-proteome-analysis-of-undiluted-vitreous-humor-in-patients-with-branch-retinal-vein-occlusion
#11
I Dacheva, M Reich, M Nobl, K Ceglowska, J Wasiak, J Siwy, P Zürbig, H Mischak, F H J Koch, J Kopitz, F T A Kretz, T Tandogan, G U Auffarth, M J Koss
BACKGROUND: The pathophysiological mechanisms of macular edema secondary to branch retinal vein occlusion (BRVO) remain unclear. OBJECTIVES: To analyze the protein profile of human vitreous of patients with BRVO and to identify specific dysregulated proteins. MATERIALS AND METHODS: Undiluted vitreous humor samples from patients with treatment naïve BRVO and 15 controls with idiopathic floaters were analyzed in this clinical-experimental study using capillary electrophoresis coupled to a mass spectrometer (CE-MS) and tandem mass spectrometry (MS/MS)...
February 28, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28241312/changes-in-retinal-microcirculation-after-intravitreal-ranibizumab-injection-in-eyes-with-macular-edema-secondary-to-branch-retinal-vein-occlusion
#12
Marie Fukami, Takeshi Iwase, Kentaro Yamamoto, Hiroki Kaneko, Shunsuke Yasuda, Hiroko Terasaki
Purpose: To evaluate the effects of an intravitreal ranibizumab (IVR) injection on the retinal microcirculation of eyes with macular edema secondary to a branch retinal vein occlusion (BRVO). Methods: Twenty-six eyes of 26 patients with macular edema due to a BRVO that had received a single IVR injection (0.5 mg/0.05 mL) were studied. The retinal microcirculation was assessed by laser speckle flowgraphy (LSFG) using the mean blur rate (MBR) and relative flow volume (RFV)...
February 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28192843/results-of-a-meta-analysis-on-intravitreal-anti-vegf-treatment-of-macular-oedema-secondary-to-branch-retinal-vein-occlusion-brvo
#13
H Gerding
Background In this meta-analysis, the outcome was analysed of intravitreal anti-VEGF (vascular endothelial growth factor) ocular therapy of macular oedema secondary to branch retinal vein occlusion; this was related to baseline and treatment parameters. Material and Methods 36 relevant publications (33 case series) were identified in a MEDLINE-based literature search, which reported on 1,759 treated eyes. Statistical analysis included description of baseline, treatment, and outcome data, linear and non-linear regression and comparison of randomised and non-randomised studies...
February 13, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28170538/microglia-activation-and-recruitment-of-circulating-macrophages-during-ischemic-experimental-branch-retinal-vein-occlusion
#14
Andreas Ebneter, Despina Kokona, Nadia Schneider, Martin S Zinkernagel
Purpose: To characterize retinal microglia activation and macrophage recruitment in experimental branch retinal vein occlusion (BRVO). Methods: Experimental BRVO was induced in Balb/c mice and histologic changes were studied. Tissue hypoxia was visualized using pimonidazole hydrochloride. Monocyte-derived retinal cells were quantified using histology and flow cytometry. To investigate the dynamics of invading blood-borne macrophages, chimera mice were generated using bone marrow grafts from Cx3cr1(gfp/gfp) mice to rescue lethally irradiated wild-type BALB/c mice...
February 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28124146/aniseikonia-in-various-retinal-disorders
#15
Fumiki Okamoto, Yoshimi Sugiura, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika
PURPOSE: The purpose was to quantify and compare the severity of aniseikonia in patients undergoing vitrectomy for various retinal disorders. METHODS: We studied 357 patients with retinal disorders including epiretinal membrane (ERM), macular hole (MH), cystoid macular edema with branch / central retinal vein occlusion (BRVO-CME / CRVO-CME), diabetic macular edema (DME), macula-off rhegmatogenous retinal detachment (M-off RD), and macula-on RD (M-on RD) as well as 31 normal controls...
January 25, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28103831/demographics-of-patients-receiving-intravitreal-anti-vegf-treatment-in-real-world-practice-healthcare-research-data-versus-randomized-controlled-trials
#16
MULTICENTER STUDY
F Ziemssen, N Feltgen, F G Holz, R Guthoff, A Ringwald, T Bertelmann, A Wiedon, C Korb
BACKGROUND: While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs. METHODS: The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO)...
January 19, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28098732/significant-reduction-of-peripapillary-choroidal-thickness-in-patients-with-unilateral-branch-retinal-vein-occlusion
#17
Hae Min Kang, Jeong Hoon Choi, Hyoung Jun Koh, Christopher Seungkyu Lee, Sung Chul Lee
PURPOSE: To evaluate changes in peripapillary choroidal thickness in patients with branch retinal vein occlusion (BRVO) over 12 months, using spectral-domain optical coherence tomography with enhanced depth imaging. METHODS: This retrospective, interventional case series included 20 treatment-naive patients with unilateral BRVO with at least 12 months follow-up. The peripapillary choroidal thickness was measured over 12 months. RESULTS: In BRVO-affected eyes, the mean peripapillary choroidal thickness was 213...
January 16, 2017: Retina
https://www.readbyqxmd.com/read/28098203/optical-coherence-tomography-angiography-microvascular-findings-in-macular-edema-due-to-central-and-branch-retinal-vein-occlusions
#18
Mastropasqua Rodolfo, Toto Lisa, Di Antonio Luca, Borrelli Enrico, Senatore Alfonso, Di Nicola Marta, Di Martino Giuseppe, Ciancaglini Marco, Paolo Carpineto
The aim of this study was to evaluate retinal and choriocapillaris vessel density using optical coherence tomography angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular edema (ME). Sixty eyes of 60 patients with CRVO or BRVO and ME and 40 healthy subjects underwent measurements of superficial and deep foveal and parafoveal vessel density (FVD, PFVD) and choricapillary density using OCTA at baseline and 60 days after intravitreal dexamethasone implant (IVDEX)...
January 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#19
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27971621/cost-effectiveness-of-intravitreal-aflibercept-ivt-afl-in-treatment-of-macular-edema-me-secondary-to-branch-retinal-vein-occlusion-brvo
#20
C Sar, S Malhan, E Oksuz, B Eldem, N Unlu, M N Alp, E Ozmert, A H Durukan, E Erdal, B Kahveci
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
44182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"